BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 8733686)

  • 21. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
    Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
    Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
    Villaron EM; Almeida J; Lopez-Holgado N; Sanchez-Guijo FM; Alberca M; Blanco B; Sanchez-Abarca LI; Lopez O; Perez-Simon JA; San Miguel JF; del Cañizo MC
    Transfus Apher Sci; 2007 Oct; 37(2):145-56. PubMed ID: 17983836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
    Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
    Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose therapy with peripheral blood progenitor cell support in patients with non-Hodgkin's lymphoma.
    Haas R; Murea S; Goldschmidt H; Döhner H; Moos M; Witt B; Eugenhart R; Wannenmacher M; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():28-35. PubMed ID: 8747986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. G-CSF during large field radiotherapy reduces bone marrow recovery capacity.
    Pape H; Orth K; Heese A; Heyll A; Kobbe G; Schmitt G; Niederbichler AD; Peiper M; Schwarz A; Boelke E
    Eur J Med Res; 2006 Aug; 11(8):322-8. PubMed ID: 17052967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma.
    Goldschmidt H; Hegenbart U; Haas R; Hunstein W
    Bone Marrow Transplant; 1996 May; 17(5):691-7. PubMed ID: 8733683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
    Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D
    Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
    Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
    Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
    Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
    Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment.
    Koç ON; Gerson SL; Phillips GL; Cooper BW; Kutteh L; Van Zant G; Reece DE; Fox RM; Schupp JE; Tainer N; Lazarus HM
    Bone Marrow Transplant; 1998 Feb; 21(4):337-43. PubMed ID: 9509966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
    Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
    Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
    Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM
    Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods.
    Venditti A; Battaglia A; Del Poeta G; Buccisano F; Maurillo L; Tamburini A; Del Moro B; Epiceno AM; Martiradonna M; Caravita T; Santinelli S; Adorno G; Picardi A; Zinno F; Lanti A; Bruno A; Suppo G; Franchi A; Franconi G; Amadori S
    Bone Marrow Transplant; 1999 Nov; 24(9):1019-27. PubMed ID: 10556963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization.
    Koenigsmann M; Jentsch-Ullrich K; Mohren M; Becker E; Heim M; Franke A
    Transfusion; 2004 May; 44(5):777-84. PubMed ID: 15104662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.